Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- Pill combinations in patients with an inadequate response to aliskiren monotherapy

Current Vascular Pharmacology

Volumn 10, Issue 6, 2012, Pages 748-755

  Glorioso, Nicola ^a   Thomas, Mathew ^b   Troffa, Chiara ^a   Argiolas, Giuseppe ^a   Patel, Samir ^c   Baek, Inyoung ^c   Zhang, Jack ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b GOVERNMENT MEDICAL COLLEGE   (India)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Amlodipine; Hypertension; Non responder; Renin angiotensin aldosterone system; Single pill combination

Indexed keywords

ALISKIREN; ALISKIREN PLUS AMLODIPINE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; EUROPE; FEMALE; FUMARATES; HUMANS; HYPERTENSION; INDIA; LEAST-SQUARES ANALYSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; TABLETS; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VENEZUELA;

EID: 84870168844     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112803520765     Document Type: Article

References (20)

1. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9-20.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
3. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
4. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
5. Copley JB, Rosario R. Hypertension: a review and rationale of treatment. Dis Mon. 2005; 51: 548-614.
6. Chrysant SG. The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs 2010; 10: 315-20.
7. Dahlof B. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. J Hum Hypertens 2009; 23: 77-85.
8. Mourad JJ, Le Jeune S, Pirollo A, Mourad C, Gaudouen Y, Lopez-Sublet M. Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. Curr Med Res Opin 2010; 26: 2263-76.
9. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.
10. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-81.
11. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24: 243-56.
12. Weir MR, Bakris GL. Combination therapy with renin-angiotensinaldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich) 2008; 10: 146-52.
13. Braun-Dullaeus RC, Zhang J, Hristoskova S, Haring DA, Liao W. First-line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension. J Clin Hypertens 2010; 12 (Suppl 1): A27 PO-22.
14. Black HR, Weinberger MH, Purkayastha D, et al. Combination aliskiren/amlodipine is more effective than amlodipine monotherapy in male and female African American subjects with stage 2 hypertension. J Clin Hypertens 2010; 12 (Suppl 1): A26 PO-20.
15. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004; 328: 634-40.
16. National Institute for Health and Clinical Excellence. Clinical Guideline 34: Hypertension: management of hypertension in adults in primary care [Online]. 2006. Available from: http://www.nice. org.uk/guidance/CG34/niceguidance/pdf/English (Accessed 21 January 2011).
17. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007; 120: 713-9.
18. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
19. Shah NR, Hirsch AG, Zacker C, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens 2009; 22: 392-6.
20. Brown MJ, McInnes GT, Cherif Papst C, Zhang J, MacDonald MT. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312-20.